The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Johnson & Johnson’s Momenta Pharmaceuticals unit is crying patent infringement against Mylan—now Viatris—plus two of the generics maker’s Indian manufacturing partners, according to a new lawsuit. But ...

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

Israel-based Teva Pharmaceutical is one of the largest global generic drug manufacturers, with a significant presence in the United States and in Western Europe. Generic drug manufacturers with large ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.

NEW YORK (Reuters) - Momenta Pharmaceuticals Inc said on Friday U.S. regulators had accepted for review its generic version of Teva Pharmaceutical Industries Ltd's multiple sclerosis drug Copaxone, ...

We are lowering our fair value estimate for Teva Pharmaceutical to $10 per share from $11, primarily as a result of our lower top-line forecast over the next two years. The company's first-quarter ...

Blue Cross and Blue Shield of Vermont and the Vermont Health Plan filed suit this week against Teva Pharmaceuticals, accusing the company of using some shady tactics to rake in money from its multiple ...